Allogene Overland Biopharm completes Shanghai facility to manufacture CAR-T products
Last month, as cell therapy player Allogene launched a study for its candidate targeting large B-cell lymphoma, its joint venture, Allogene Overland Biopharm put the finishing touches on a new CAR-T manufacturing facility in Shanghai.
In an email to Endpoints News, Allogene said the process from design to completion took the company just under a year, which was “truly remarkable” given that there was also a period in which Shanghai was in lockdown as a result of the Covid-19 pandemic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.